RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 26% Y-o-Y for Q4 FY23, maintaining the upward trajectory in EBITDA margins, which improved from 14.2% to 15.0% Y- o-Y. Revenue from operations at Rs 118.49 crores registered a growth of 14% Y-o-Y for Q4 FY23.

For full year FY23 too, the company posted a jump in PBT by 25% Y-o-Y and recorded EBITDA margin expansion from 20.3% to 21.0% Y-o-Y. Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23.

Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q4 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong result despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by a healthy 14% and 26% respectively Y-o-Y. EBITDA margins’ consistent upward trajectory has continued for the last 5 years, growing from 10.4% (FY19) to 15.9% (FY20) to 18.2% (FY21) to 20.3% (FY22) to 21.0% (FY23). The Company continues to remain debt-free with the highest- ever net cash flow generated from operations in full year FY23.

Domestic Formulations business, the biggest contributor to the company’s business, recorded robust growth both in value and volume - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments.

International Formulations business has also shown robust growth, while emerging as another growth driver for the Company, registering healthy growth in both sales and profits. Company is investing in plant upgradation and capacity expansion in both plants as well as working on building a healthy product pipeline to accelerate exports. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”